Acute Pancreatitis
Conditions
Interventions
Control Group:Standard treatment
Thoracic Epidural Analgesia Group:Thoracic epidural analgesia on top of standard treatment
Sponsors
Run Run Shaw Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1)Age between 18 and 70 years (including borderline values). 2)Patients admitted to the hospital within 7 days of onset with a diagnosis of acute pancreatitis. 3)Admitted to ICU with single or multiple organ failure. 4)ASA class 1-III. 5)Voluntarily participate in this study and sign the informed consent form. If the subject is incapable of reading and signing the informed consent form for reasons such as incapacitation, his/her guardian will be required to act on his/her behalf in the informed process and sign the informed consent form. If the subject cannot read the informed consent form (e.g., illiterate subjects), a witness will be required to witness the informed process and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1)Patients who are breastfeeding and pregnant, or planning pregnancy within 6 months. 2)Patients with recurrent acute pancreatitis, chronic pancreatitis or pancreatic tumor-related pancreatitis. 3)Patients who have undergone surgical drainage and debridement and need emergency ERCP treatment. 4)Patients who have previously undergone cardiopulmonary resuscitation and have not recovered neurological function. 5)Patients with a history of severe cardiovascular, respiratory, renal, hepatic, hematologic, malignant neoplasm or immune diseases: patients with heart failure greater than NYHA Cardiac Function Class II; active myocardial ischemia within 60 days of cardiovascular intervention; history of cirrhosis; patients with chronic renal disease, creatinine clearance <40 mL/min; chronic obstructive pulmonary disease requiring home oxygen therapy. 6)Local anesthetic drug allergy. 7) anatomical variations, unable to perform "thoracic epidural analgesia". 8)Coagulation disorders or those who are on anticoagulation therapy. 9)Participation in other interventional clinical studies in the last 3 months. 10) Other conditions that, in the judgment of the investigator, make them unsuitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in the profile of systemic inflammatory response syndrome and organ dysfunction after inclusion;intra-abdominal pressure;Rest pain and motion pain; | — |
Secondary
| Measure | Time frame |
|---|---|
| Indicators of peripheral blood inflammation and immunity;Intestinal Microbiota;Total ICU treatment time;Patient treatment costs;vital signs;Incidence, timing and location of hemorrhages requiring interventional treatment;Incidence, timing and location of gastrointestinal perforations or fistulas requiring interventional treatment;Incidence of other adverse events; | — |
Countries
China
Contacts
Public ContactHong Yu
Run Run Shaw Hospital, Zhejiang University School of Medicine
Outcome results
None listed